Reason for request
First listing
Summary of opinion
Favourable opinion for reimbursement only “as an add-on to standard therapy, including first-line immunosuppressants, for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive, who remain symptomatic.”
Unfavourable opinion for reimbursement in the other situations covered by the MA indication.
Clinical Benefit
| Substantial |
The clinical benefit of RYSTIGGO (rozanolixizumab) is substantial only as an add-on to standard therapy, including first-line immunosuppressants, for the treatment of generalised myasthenia gravis (gMG) in adultpatients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive, who remain symptomatic.
|
See also
HAS opinions and decisions
03/05/2024
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
VpstLpVX9HhXEZG3
